12:00 AM
 | 
Jun 03, 2002
 |  BioCentury  |  Product Development

Play it again, Wilex

German cancer play Wilex AG has started a Phase III trial enrolling 540 breast cancer patients with high risk of developing metastases. But the study is not just one of thousands of cancer studies; indeed, Wilex is not even testing one of its compounds. Instead, the study will investigate the efficacy of Docetaxel, a taxotere developed by Aventis S.A.

The ADEBAR (Adjuvant Docetaxel vs. Epirubicin Based Regimen) trial will investigate the efficacy of Docetaxel in several combinations with anthracycline chemotherapy. At the same time, Wilex will collect clinical data, including gene expression profiles and marker protein concentrations, which could help it to select potential combination therapies for its own small molecule cancer compounds.

The approach applies the first principles of predictive medicine that were the basis of the company's formation.

According to Wilex CEO Olaf Wilhelm, there are four reasons to undertake the trial: "For one, no one...

Read the full 733 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >